Learn more about whether Pegasystems Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Learn more about whether LiveRamp Holdings, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

The Dow fell Friday after the White House said tariffs begin on Saturday. The S&P 500 and Nasdaq also finished lower. The market also reacted to PCE inflation data.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...